MYH14 and breast carcinoma: Treatment of MDA-MB-231 human breast cancer cells with BDP00005290 (BDP5290) was sufficient to fully inhibit MLC phosphorylation (pMLC) by targeting both cytoplasmic and peripheral actin-myosin bundles, in contrast to the ROCK selective inhibitor Y27632 that preferentially reduced cytoplasmic pMLC.